Tommy DiRaimondo, Ph.D.

Tommy joined the Janux Therapeutics team in May 2018 and currently serves as Chief Scientific Officer. He manages the internal and external research operations and has been an integral part in the creation and reduction to practice of key technologies protected by the ever-growing Janux intellectual property portfolio. Before Janux, Tommy was the co-founder of Sitari Pharmaceuticals based upon his graduate work at Stanford University with Professor Chaitan Khosla. Tommy was a key leader in the Sitari drug discovery and development program, whose successful culmination was the acquisition by GlaxoSmithKline.

Tommy earned his Ph.D. in Chemical Engineering from Stanford University, his M.S.E. in Pharmaceutical Engineering, and his B.S.E in Chemical Engineering from the University of Michigan, Ann Arbor.